ARV-471, an estrogen receptor (ER) PROTAC® degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2 negative breast cancer: phase 1b cohort (part C) of a phase 1/2 study Read More »
Clearance of Pathologic Proteins in Neurodegeneration by Heterobifunctional Degrader Molecules Read More »
Phase 1/2 Study of ARV-110, an Androgen Receptor PROTAC® Degrader, in Metastatic Castration-Resistant Prostate Cancer Read More »
Potent and Orally Bioavailable BCL6 PROTAC® Degraders Demonstrate Efficacy in Pre-Clinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) Read More »
First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer Read More »
Heterobifunctional Degrader Molecules that lead to the clearance of Pathologic Proteins in Neurodegeneration Read More »
Discovery of ARV-110, a first in class androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer Read More »
The Discovery of ARV-471, an Orally Bioavailable Estrogen Receptor Degrading PROTAC® for the Treatment of Patients with Breast Cancer Read More »
A New Therapeutic Strategy for Tauopathies: Discovery of Highly Potent Brain Penetrant Tau PROTAC® Degrader Molecules Read More »
